What we're reading, January 8, 2016: HHS releases report with full Obamacare enrollment information for all 50 states and the District of Columbia; the expansion of the biosimilars in 2016; and promising Ebola treatment found not effective.
The first HHS report during the third open enrollment period of the Affordable Care Act to include data for all 50 states and the District of Columbia revealed that more than 11.3 million people signed up for coverage through the health insurance marketplaces. This includes the 8.6 million in the 38 states using HealthCare.gov and the 2.7 million people in the 13 states using their own marketplaces. Nearly one-fourth of all plan selections were made by individuals between the ages of 18 and 34. The data is for enrollment through December 26, 2015.
In 2016, the expansion of the biosimilar pipeline will be driven by a number of factors, including growing approvals in Europe and the US and expiring patents, according to an article by the senior medical director of Quintiles Asia and published in India’s The Financial Express. The second wave of biosimilars includes biologics with patents expiring between 2015 and 2020, such as the top-selling products Humira, Enbrel, Rituxan/MabThera, Avastin, Herceptin, and Remicade. There are already more than 160 biosimilars in different stages of development for these drugs.
The most promising treatment for patients with Ebola has been found to be not effective, according to a study published in The New England Journal of Medicine. The experimental treatment used blood plasma from Ebola survivors, who had developed antibodies to neutralize the virus, reported The New York Times. However, the small study of 84 patients found that the survival rate was not significantly better than the rate for patients who did not receive blood transfusions.
Age Alone Is No Barrier to Allo-HCT for AML, Data Indicate
April 17th 2024A new study is among the largest real-world analyses to date to assess trends over time and predictive factors for older patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic cell transplantation (allo-HCT).
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from the Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen